Clinical Trial Management Committee (CTMC)
The Clinical Trial Management Committee (CTMC) consists of A-TANGO scientists that coordinate and supervise the clinical study. The CTMC is responsible for setting up and implementing the logistics around the clinical study. It also provides support to consortium members concerning the clinical trials and reviews the results to assess whether changes to the study protocol are necessary.
Impact Board (IB)
The Impact Board (IB) consists of junior and senior members of A-TANGO, from academia and industry, as well as patient representatives. The IB approves the communication plan (WP7) for optimally disseminating and exploiting the project’s results, monitors the steps being taken, and oversees and evaluates the internal and external dissemination of the project’s results and knowledge gain. The IB also assigns the responsibility for filing and protecting novel intellectual property (IP), and develops and monitors exploitation agreements for new IP.
IB Chair & Innovation Manager
Dr. Annarein J. C. Kerbert (MD, PhD)
Scientific and Ethical Advisory Board (SEAB)
The Scientific and Ethical Advisory Board (SEAB) is an external consultative body which is formed to ensure and improve the scientific performance and the quality of results of A-TANGO. The SEAB advises the General Assembly (GA) and the Project Management Office (PMO) upon request, and provides non-binding advice as decision making support. Members of the SEAB are cordially invited to attend the annual GA meetings in order to monitor the progress within each work packages, assess the scientific quality, and to provide critique and feedback, but do not have a right to vote. The SEAB will also consider and mention any ethical issues which may require stronger attention.
Prof. Dr. emeritus Tilman Sauerbruch
Prof. Dr. emeritus Geoffrey Dusheiko
Data and Safety Monitoring Committee (DSMC)
The members of the Data and Safety Monitoring Committee (DSMC) are independent of the clinical study of A-TANGO and are also not part of the sponsoring organisation. The DSMC reviews any issues concerning the safety of the study participants (e.g. by reviewing serious adverse events), identifies strengths and weaknesses of the data storage, and reviews the integrity of the data and potential statistical issues (e.g. selection-bias, cross-over, failure-to-diagnose, failure-to-treat, or failure-to-follow-up). Following the completion of the clinical trial, the DSMC assists in the interpretation of the final results and will revise and approve the main publication about the outcome of A-TANGO’s clinical trial.